Here's the email I sent Chuka Umunna on 18 Oct:
Dear Mr Umunna
I
am contacting you about the drug re-purposing Bill to ask for your
support to see it become Law. I believe it comes before the house on
November 6. I attach some documents setting out the case for the Bill
and please excuse me if you are already familiar with the arguments.
Breakthroughs
in research have meant that several existing drugs have been found to
be effective in treating conditions other than the ones they were
originally made and patented for. They are referred to as “off patent”
drugs. Repurposing these could have potentially huge benefits for many
people suffering from conditions like multiple sclerosis (MS) and Cancer.
They can be supplied at low cost by Generic Drug companies. The annual
treatment for a patient may be less than £1,000 versus over 20x the cost
for patented alternatives if in fact they exist. The savings would be
of great benefit to patients, the NHS and the taxpayer, and could lead
to treatment for many people whose treatment is denied by NICE on the
grounds of cost.
However,
drugs need to be licensed and approved for their new uses in order to
be made available and there is little commercial incentive for
pharmaceutical companies, who normally sponsor this process, to do so
for off patent treatments. This is largely because prices generally fall
a great deal once the patent has expired. There
is no mechanism in place to enable licensing of drugs for uses other
than their original purpose. Even if a doctor can refer to strong
evidence in support of prescribing an off-patent drug to a patient, they
would likely be put off by the potential personal liability they may
face in doing so.
There
are thus political, legal and commercial barriers in place to
prescribing off patent drugs. The Bill seeks to overcome these barriers
by obliging the Government to act
in the public interest through the process of the Medicines and
Healthcare Regulatory Agency (MHRA) to license and approve off-patent,
repurposed drugs for use on the NHS.
The
Bill is strongly supported by medical charities and specialists in the
NHS, including myself - I am a Reader in Clinical Neurology at Queen Mary University of London &
Consultant Neurologist at Barts Health NHS Trust. As a clinical
academic with an interest in MS, I know that early
effective treatment of people with MS is key for a beneficial long term
outcome. I therefore have a particular interest in the re-purposing of
Cladribine, a drug licensed in the UK for patients with hairy cell
leukaemia. There is evidence from phase III trials that Cladribine is
highly effective and safe for people with MS. The annual cost of
Cladribine treatment in MS would be under £1,000 compared to licensed
drugs of lesser efficacy that cost 20x or more. I would be very happy
to expand on this example further if you are interested and have the
time; just call me on my mobile xxx.
For now, I do hope you are able to support the Bill. Please let me know if there is anything further I can do to promote it.
With best wishes
Sincerely Yours,
Klaus Schmierer
I'll keep watching out for comments by my MP, over and above his auto-reply...
No comments:
Post a Comment